Since the IMpower133 trial first demonstrated that immunotherapy combination with chemotherapy could improve the survival of patients with ES-SCLC, it has been further confirmed in subsequent several trials of phase 3 of PD-1/PD-L1 inhibitors plus chemotherapy in the first-treatment of ES-SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.